New drug combo trial offers hope for transplant patients with severe immune reaction
Disease control
Recruiting now
This early-stage study is testing whether adding fostamatinib to the standard drug ruxolitinib is safe and effective for chronic graft-versus-host disease that doesn't respond well to steroid treatment. The trial will enroll about 30 adults who have had a stem cell transplant and…
Phase: PHASE1 • Sponsor: Stefanie Sarantopoulos, MD, PhD. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC